Mefloquine is an anti-malarial drug that can have many different side effects. Some of these can be difficult to handle if you’re not prepared. Mefloquine was prescribed for a large number of military ...

Researchers from LSTM Cochrane Infectious Diseases Group publish two systematic reviews this week about the safety of mefloquine (Lariam) for preventing malaria in travelers. "Mefloquine is at least ...

Mefloquine, mainly sold as Lariam, is used to treat or prevent malaria – a parasitic illness transmitted by mosquitoes in tropical regions. Despite significant reductions, malaria causes more than 200 ...

Early in the morning of March 11, 2012, Army staff sergeant Robert Bales left his remote outpost in an impoverished region of Kandahar Province, Afghanistan and killed 16 people in two nearby villages ...

I am a wildlife photographer who frequently spends significant time in malarious areas, especially Africa and rainforests. I currently use mefloquine (Lariam) and experience no side effects. Follow-up ...

Learn everything you need to know about Mefloquine-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Objective: To compare the efficacy and tolerability of mefloquine and proguanil in malaria prophylaxis in sickle cell anaemia. Design: Nonblind, prospective, multicentre study. Participants: The study ...

The federal government is now facing three lawsuits from eight people over the military’s use of mefloquine. The controversial anti-malarial drug was used by the Canadian Forces for its members ...

Canadian soldiers who are deployed to regions where malaria is prevalent will no longer be offered mefloquine as a first option for preventing the disease, the military has decided after a completing ...

The antimalarial drug mefloquine has come under renewed fire from former Canadian soldiers who say the medication left them with anxiety, paranoia, depression, dizziness and permanent psychiatric ...

A team of scientists from Japan has identified the approved antimalarial agent, mefloquine, as a potential candidate to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.